News
Carbon

CARBON Newsletter (3 May) - Your Latest News About CRISPR in AgroBio

Some of the best links we picked up around the internet

By: Gorm Palmgren - May. 3, 2022

CRISPR AgroBio News (CARBON) is a new initiative from CRISPR Medicine News. CARBON will bring you the latest news on how CRISPR can shape agriculture for the future to guarantee food security in times of population growth and climate change.

To get more CRISPR AgroBio News delivered to your inbox, sign up to the free weekly CARBON Newsletter here.

Top picks

  • Federal authorities in Belgium have granted permission to perform three new field trials with CRISPR gene-edited maise that researchers at VIB have developed. The plants in question have 1) improved tolerance to DNA damage caused by UV-light thanks to a mutation in the transcription factor ZmNAC52, 2) better digestibility through reduced content of lignin in the cell walls, and 3) improved tolerance to prolonged drought through increased chromatin condensation that causes growth to pause.
  • Enhanced rice grain yield has been obtained by overcoming the trait tradeoff between panicle number and size. The achievement was made through CRISPR-based targeted deletion of a 54-base pair cis-regulatory element in the Ideal Plant Architecture 1 (IPA1) gene that increases grains per panicle but reduces tillers. The Chinese researchers suggest that targeting gene regulatory regions should help dissect tradeoff effects and provide a rich source of targets for breeding complementary beneficial traits.

Technical advances

Disease control

Nutritional quality

Agronomic traits

Regulation and opinion

Reviews

Meetings and webinars

Tags

HashtagArticleHashtagNewsHashtagCARBONHashtagCARBON Newsletter

News: CARBON Newsletter (3 May) - Your Latest News About CRISPR in AgroBio
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid tumors, (NCT05361174)
Sponsors:
Iovance Biotherapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine